exv99w1

Exhibit 99.1



	Contacts:
	Martha Goldberg Aronson Investor Relations 763-505-2694		Marybeth Thorsgaard Public Relations 763-505-2644

MEDTRONIC REPORTS SECOND QUARTER REVENUE GROWTH OF 11 PERCENT

Growth Driven by New Product Introductions and Share Gains across Broad Business Portfolio

	•		Revenue of $3.075 billion grew 11% over the prior year’s quarter

	•		Double digit revenue growth in Spinal and Navigation, Vascular, Neurological, Diabetes and Emergency Response Systems reflects strength of diversified portfolio

	•		Implantable Cardioverter Defibrillator (ICD) revenue grew 14% sequentially and 4% over the prior year’s quarter from strong share gains

	•		Diluted EPS of $0.59 grew 13% compared to prior year’s quarter adjusted for stock option expense and certain gains and charges

MINNEAPOLIS — November 20, 2006 — Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2007 which ended October 27, 2006.

Medtronic recorded second quarter revenue of $3.075 billion, an 11 percent increase over the $2.765 billion reported in the second quarter of the prior fiscal year. On a constant currency basis, revenue growth was 10 percent with a positive currency translation impact of $33 million. As reported, second quarter fiscal year 2007 net earnings were $681 million, or $0.59 per diluted share, representing a decrease of 12 percent over the same quarter last year. However, EPS grew 13 percent after adjusting last year’s second quarter for stock option expensing and special gains and charges to make a more meaningful comparison.

“Revenue in all major businesses grew over the prior year period and sequentially over the first quarter as we gained share in all of our major product lines,” said Art Collins, Medtronic chairman and chief executive officer. “These results reflect the strength of our broad and diversified business portfolio that serves many of the fastest growing segments in medical technology.”

Unless otherwise noted, the comparisons made are on an “as reported basis,” not on a constant currency basis. Any references to quarterly revenue figures increasing or decreasing are in comparison to the second quarter of fiscal year 2006.

Cardiac Rhythm Disease Management

Cardiac Rhythm Disease Management (CRDM) revenue of $1.363 billion grew 6 percent. Medtronic’s largest product line, ICDs, generated second quarter revenue of $764 million, an increase of 4 percent over the same quarter last year and 14 percent over the first quarter, resulting in strong product market share gains worldwide. Worldwide pacing revenue of $473 million in the quarter grew 3 percent. Medtronic now holds an estimated 56 percent of the worldwide ICD market and more than 50 percent of the worldwide pacemaker market. Emergency Response Systems second quarter revenue of $111 million, increased 37 percent.

CRDM quarterly highlights include:

	•		Solid share gains in both the U.S. and international ICD markets reflect the positive acceptance of the Concerto™/Virtuoso™ ICD and CRT-D, which feature Medtronic’s Connexus wireless telemetry.

	•		Data from the CARE-HF (Cardiac Resynchronization in Heart Failure) study presented at the 2006 European Society of Cardiology/World Congress of Cardiology in September, demonstrated that Cardiac Resynchronization Therapy significantly reduces mortality in heart failure patients.

	•		Medtronic launched its newest pacing platform, the Adapta™, Versa™ and Sensia™ family of products, which incorporates unique capabilities, including MVP, automaticity and the connection to CareLink^®.

	•		The Medtronic Carelink Network, available on both pacing and ICD platforms, continues to expand, with more than 1,000 clinics monitoring nearly 95,000 patients in the U.S.

Spinal and Navigation

Spinal and Navigation revenue of $625 million grew 16 percent. Spinal revenue increased 16 percent with the Biologics product line growing 33 percent. All major geographies achieved double digit revenue growth.

Spinal and Navigation quarterly highlights include:

	•		Worldwide INFUSE^® Bone Graft revenue grew 36 percent, driven by expanded surgeon adoption. On November 9, a Food and Drug Administration (FDA) advisory panel recommended approval of INFUSE Bone Graft for use in oral maxillofacial procedures.

	•		An FDA advisory panel unanimously voted to recommend approval of the PRESTIGE^® Cervical Disc System. The PRESTIGE Disc is the first in a portfolio of artificial disc replacements designed to maintain motion while replacing a diseased disc that is removed from a patient’s cervical spine. Approval is anticipated in the U.S. before the end of the fiscal year.

	•		ARCUATE™ and ARCUATE™ XP, which provide new treatments for patients who suffer from painful and often disabling symptoms associated with a vertebral compression fracture, were launched in the U.S.

	•		The CD HORIZON^® product line was expanded with the worldwide launch of CD HORIZON LEGACY™ PEEK Rod System for posterior spinal fusion procedures, the CD HORIZON ENGAGE PLATE System for lumbar fusion surgery and the CD HORIZON LEGACY™ VCM Instrument Set to treat scoliosis.

Vascular

Vascular revenue of $287 million grew 28 percent. Strong second quarter results were driven by Coronary Vascular which generated revenue of $217 million, representing growth of 29 percent. The Endovascular and Peripheral Vascular business reported revenue growth of 23 percent.

Vascular quarterly highlights include:

	•		The Endeavor^® Drug-Eluting Coronary Stent, now commercially released in more than 100 countries outside the U.S., continued to gain global product market share, as a result of favorable safety and efficacy data and its ease of deliverability. The final module of the Endeavor PMA was submitted this month and FDA approval and U.S. launch is anticipated in calendar 2007.

	•		Positive clinical results from the ENDEAVOR II pivotal trial were published in the medical journal CIRCULATION. The results provided further evidence of the safety and effectiveness of the Endeavor drug-eluting stent, with a clinically and statistically significant

treatment effect that is being sustained over time. Additionally, Medtronic reported excellent patient safety data on Endeavor at last Month’s Transcatheter Cardiovascular Therapeutics symposium in Washington, D.C.

•

Medtronic also announced the initiation of the largest ever randomized stent trial. The PROTECT clinical study will assess and compare key safety measures of two drug-eluting stents. The trial will compare the Medtronic Endeavor drug-eluting coronary stent versus a competing stent.

Neurological

Neurological revenue of $291 million grew 15 percent. The segment’s largest business, which includes implantable pumps and neuro stimulators, generated second quarter revenue of $238 million, increasing 17 percent. Revenue in the Gastroenterology and Urological business grew 10 percent.

Neurological quarterly highlights include:

	•		RestoreADVANCED™ and PrimeADVANCED™, two new neurostimulation systems for the treatment of chronic pain, were launched in the U.S. Enhanced programming capabilities will help aid physicians in targeting the specific stimulation area on the spinal cord to provide optimal pain relief.

	•		Results of a major randomized controlled multi-center study were published in the August 31 issue of the New England Journal of Medicine demonstrating that Activa deep brain stimulation therapy combined with medication is significantly more effective than medication alone in treating motor symptoms of advanced Parkinson’s disease.

	•		The launch of InterStim^® II was completed, which drove U.S. InterStim revenue growth of 41 percent. The InterStim II neurostimulation system is used for the treatment of overactive bladder and urinary retention.

Diabetes

Diabetes revenue of $212 million grew 19 percent. Second quarter results were driven by strong sales of insulin pumps with solid double digit growth reported in all geographies.

Diabetes quarterly highlights include:

	•		Insulin pump sales were driven by strong demand for the Paradigm^® REAL-time System, the only product on the market that integrates continuous glucose monitoring and insulin pump functionality.

	•		A non-sensor augmented pump that operates in 16 languages was launched, targeting markets in Europe and the Middle East. Additionally, the 712E insulin pump with Chinese language capability was launched in China.

	•		The GuardControl study evaluating continuous glucose monitoring versus self monitored blood glucose meters was accepted by Diabetes Care Journal for publication.

Cardiac Surgery

Cardiac Surgery revenue of $168 million grew 4 percent.

Cardiac Surgery quarterly highlights include:

	•		Melody™ and Ensemble™, the world’s first transcatheter pulmonic valve system, received CE Mark approval for commercial sale in Europe. This technology provides a catheter-based approach to pulmonic valve replacement for patients with congenital heart defects, thereby reducing the number of open-heart surgeries required during their lifetime.

	•		Two new products, the Performer™ Cardio Bypass System (CPB) and the Octopus^® Evolution tissue stabilizer were fully launched. The Performer CPB is a more compact console, one-third the size of traditional heart-lung machines. The Octopus Evolution continues Medtronic’s series of innovative cardiac surgery instruments for revascularization surgery.

Ear, Nose and Throat (ENT)

ENT revenue of $129 million grew 7 percent. Power Systems, including powered drills and endoscopic shavers and Nerve Integrity Monitoring, all reported double digit growth. Neurologic Technology second quarter revenue increased 12 percent due to strong growth from cranial and spinal surgical tools as well as continued success of the Strata™ Valve, which is increasingly being used to treat Normal Pressure Hydrocephalus.

Webcast Information
Medtronic will host a webcast today, Nov. 20 at 4:30 pm EST (3:30 CST), to provide information about its businesses for the public, analyst and news media. This quarterly webcast can be accessed by clicking on the Investor Relations link on the Medtronic home page at www.medtronic.com., and this earnings release will be archived at www.medtronic.com/newsroom. Within 24 hours, a replay of the webcast and a transcript of the company’s prepared remarks will be available in the “Presentations & Transcripts” section of the Investor Relations homepage.

Medtronic, Inc., headquartered in Minneapolis, is the world’s leading medical technology company, alleviating pain, restoring health and extending life for people with chronic disease. Its Internet address is www.medtronic.com.

-end-

This press release contains forward-looking statements, including statements regarding clinical trials, new products, market growth and market acceptance and other developments, which are subject to risks and uncertainties, such as competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, general economic conditions and other risk and uncertainties described in Medtronic’s Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements.

MEDTRONIC, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)
(in millions, except per share data)


	Three months ended						Six months ended
	October 27, 2006			October 28, 2005			October 27, 2006			October 28, 2005
Net sales	$	3,075		$	2,765		$	5,972		$	5,456

Costs and expenses:
Cost of products sold		795			695			1,527			1,349
Research and development expense		320			275			619			538
Selling, general, and administrative expense		1,036			903			2,020			1,786
Special charges		—			100			—			100
Certain litigation charges		—			—			40			—
Purchased in-process research and development (IPR&D)		—			—			—			364
Other expense, net		50			41			116			91
Interest income		(37	)		(14	)		(76	)		(29	)

Total costs and expenses		2,164			2,000			4,246			4,199


Earnings before income taxes		911			765			1,726			1,257

Provision for income taxes		230			(52	)		446			120


Net earnings	$	681		$	817			1,280		$	1,137


Earnings per share:
Basic	$	0.59		$	0.68		$	1.11		$	0.94

Diluted	$	0.59		$	0.67		$	1.10		$	0.93


Weighted average shares outstanding:
Basic		1,149.3			1,208.6			1,151.4			1,209.6
Diluted		1,159.4			1,222.5			1,161.9			1,222.4

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP NET EARNINGS
TO CONSOLIDATED ADJUSTED NET EARNINGS
(Unaudited)
(in millions, except per share data)


	Three months ended		Three months ended
	October 27, 2006		October 28, 2005
Net earnings, as reported	$	681	$	817
Special charges		—		66	(a)
Income tax adjustments		—		(225	) (b)
Stock-based awards		—		(25	) (c)

Adjusted net earnings	$	681	$	633

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP DILUTED EPS
TO CONSOLIDATED ADJUSTED DILUTED EPS
(Unaudited)


	Three months ended		Three months ended
	October 27, 2006		October 28, 2005
Diluted EPS, as reported	$	0.59	$	0.67
Special charges		—		0.05	(a)
Income tax adjustments		—		(0.18	) (b)
Stock-based awards		—		(0.02	) (c)

Adjusted diluted EPS	$	0.59	$	0.52


(a)		The $66 million ($0.05 per share) special charge represents an after-tax charitable donation ($100 million pre-tax) made to The Medtronic Foundation. In addition to disclosing special charges that are determined in accordance with GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this donation. The Company has not made a similar donation to The Medtronic Foundation since fiscal year 2002. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates this donation when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

(b)		The $225 million ($0.18 per share) tax adjustment represents a $225 million tax benefit associated with the reversal of reserves resulting from favorable agreements reached with the U.S. Internal Revenue Service involving the review of fiscal years 1997 through 2002 domestic income tax returns. In addition to disclosing the provision for income taxes that is determined in accordance with GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this tax adjustment. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and is useful for period over period comparisons of such operations, specifically the effective tax rate. Medtronic management eliminates this tax adjustment when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

(c)		The Company adopted SFAS No. 123(R) effective April 29, 2006 and began to recognize compensation expense associated with all stock-based awards. Prior to fiscal year 2007, the Company accounted for stock-based awards under APB No. 25, and thus the Company only recognized compensation expense related to restricted stock awards and restricted stock units. Under SFAS No. 123(R) compensation expense is recongized on all stock-based awards including stock options, employee stock purchase plans and restricted stock awards/units. The $25 million ($0.02 per share), net of statutory tax ($35 million pre-statutory tax), represents the incremental expense that would have been recorded had the Company accounted for stock-based awards in accordance with SFAS No. 123(R) in fiscal year 2006. Total stock-based compensation including stock options, restricted stock awards/units and employee stock purchase plans was $44 million (pre-statutory tax) in the second quarter of fiscal year 2007 and pro-forma total stock-based compensation including stock options, restricted stock awards/units and employee stock purchase plan was $41 million (pre-statutory tax) in the second quarter of fiscal year 2006. Below is a listing, by income statement line item, of the pre-statutory tax total stock-based compensation expense recognized in second quarter of fiscal year 2007 and the pro forma stock-based compensation expense for second quarter of fiscal year 2006.


	Three months ended		Three months ended
	October 27, 2006		October 28, 2005
Cost of products sold	$	4	$	4
Research and development expense		10		10
Selling, general, and administrative expense		30		27

	$	44	$	41

Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and is useful for period over period comparisons of such operations. Medtronic management applies the provisions of SFAS No. 123(R) to fiscal years 2006 and prior when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP NET EARNINGS
TO CONSOLIDATED ADJUSTED NET EARNINGS
(Unaudited)
(in millions, except per share data)


	Six months ended			Six months ended
	October 27, 2006			October 28, 2005

Net earnings, as reported	$	1,280		$	1,137
Special charges		—			66	(b)
Certain litigation charges		40	(a)		—
IPR&D charges		—			295	(c)
Income tax adjustments		—			(225	) (d)
Stock-based awards		—			(57	) (e)

Adjusted net earnings	$	1,320		$	1,216

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP DILUTED EPS
TO CONSOLIDATED ADJUSTED DILUTED EPS
(Unaudited)


	Six months ended			Six months ended
	October 27, 2006			October 28, 2005
Diluted EPS, as reported	$	1.10		$	0.93
Special charges		—			0.05	(b)
Certain litigation charges		0.04	(a)		—
IPR&D charges		—			0.24	(c)
Income tax adjustments		—			(0.18	) (d)
Stock-based awards		—			(0.05	) (e)

Adjusted diluted EPS	$	1.14		$	0.99


(a)		The $40 million ($0.04 per share) after-tax certain litigation charge is related to the settlement agreement reached with the United States (U.S.) Department of Justice which requires the government to seek dismissal of two qui tam civil suits pending against Medtronic. In addition to disclosing certain litigation charges that are determined in accordance with U.S. generally accepted accounting principles (GAAP), Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding these litigation charges. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates these litigation charges when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

(b)		The $66 million ($0.05 per share) special charge represents an after-tax charitable donation ($100 million pre-tax) made to The Medtronic Foundation. In addition to disclosing special charges that are determined in accordance with GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this donation. The Company has not made a similar donation to The Medtronic Foundation since fiscal year 2002. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates this donation when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

(c)		The $295 million ($0.24 per share) after-tax IPR&D charges ($364 million pre-tax) represents the cumulative impact of pre-tax charges of $169 million related to a technology acquired through the purchase of Transneuronix, Inc. that had not yet reached technological feasibility and had no future alternative use, $175 million related to the purchase of spinal technology based devices owned by Gary Michelson and Karlin Technology, Inc. that had not yet reached technological feasibility and had no future alternative use, and $20 million related to a cross-licensing agreement with NeuroPace, Inc. for patent and patent applications on products that had not yet reached technological feasibility and had no future alternative use, collectively the IPR&D charges. In addition to disclosing IPR&D charges that are determined in accordance with GAAP, Medtronic managment believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding these IPR&D charges. These IPR&D charges resulted from facts and circumstances that vary in frequency and/or impact on continuing operations. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates these IPR&D charges when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

(d)		The $225 million ($0.18 per share) tax adjustment represents a $225 million tax benefit associated with the reversal of reserves resulting from favorable agreements reached with the U.S. Internal Revenue Service involving the review of fiscal years 1997 through 2002 domestic income tax returns. In addition to disclosing the provision for income taxes that is determined in accordance with GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this tax adjustment. Management believes that the resulting non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and is useful for period over period comparisons of such operations, specifically the effective tax rate. Medtronic management eliminates this tax adjustment when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

(e)		The Company adopted SFAS No. 123(R) effective April 29, 2006 and began to recognize compensation expense associated with all stock-based awards. Prior to fiscal year 2007, the Company accounted for stock-based awards under APB No. 25, and thus the Company only recognized compensation expense related to restricted stock awards and restricted stock units. Under SFAS No. 123(R) compensation expense is recongized on all stock-based awards including stock options, employee stock purchase plans and restricted stock awards/units. The $57 million ($0.05 per share), net of statutory tax ($78 million pre-statutory tax), represents the incremental expense that would have been recorded had the Company accounted for stock-based awards in accordance with SFAS No. 123(R) in fiscal year 2006. Total stock-based compensation including stock options, restricted stock awards/units and employee stock purchase plans was $94 million (pre-statutory tax) for the six months ended October 27, 2006 and pro-forma total stock-based compensation including stock options, restricted stock awards/units and employee stock purchase plans was $90 million (pre-statutory tax) for the six months ended October 28, 2005. Below is a listing, by income statement line item, of the pre-statutory tax total stock-based compensation expense recognized in six months ended October 28, 2006 and the pro forma stock-based compensation expense for six months ended October 28, 2005.


	Six months ended		Six months ended
	October 27, 2006		October 28, 2005
Cost of products sold	$	10	$	10
Research and development expense		22		22
Selling, general, and administrative expense		62		58

	$	94	$	90

MEDTRONIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)


	Six months ended
	October 27,			October 28,
	2006			2005
	(dollars in millions)
OPERATING ACTIVITIES:
Net earnings	$	1,280		$	1,137
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization		277			268
Purchased in-process research and development		—			364
Provision for doubtful accounts		21			4
Deferred income taxes		(251	)		192
Stock-based compensation		94			12
Excess tax benefit from exercise of stock-based awards		(11	)
Change in operating assets and liabilities:
Accounts receivable		(179	)		(74	)
Inventories		(143	)		(189	)
Accounts payable and accrued liabilities		199			(740	)
Other operating assets and liabilities		20			45



Net cash provided by operating activities		1,307			1,019

INVESTING ACTIVITIES:
Acquisitions, net of cash acquired		(8	)		(285	)
Purchase of intellectual property		(102	)		(794	)
Additions to property, plant and equipment		(251	)		(229	)
Purchases of marketable securities		(7,275	)		(1,922	)
Sales and maturities of marketable securities		6,787			1,013
Other investing activities, net		(44	)		(12	)



Net cash used in investing activities		(893	)		(2,229	)

FINANCING ACTIVITIES:
(Decrease) increase in short-term borrowings, net		(1,814	)		386
Increase in long-term debt, net		1			994
Dividends to shareholders		(254	)		(232	)
Issuance of common stock		113			254
Excess tax benefit from exercise of stock-based awards		11			—
Repurchase of common stock		(398	)		(564	)



Net cash (used in) provided by financing activities		(2,341	)		838

Effect of exchange rate changes on cash and cash equivalents		23			88


Net change in cash and cash equivalents		(1,904	)		(284	)

Cash and cash equivalents at beginning of period		2,994			2,232



Cash and cash equivalents at end of period	$	1,090		$	1,948


Supplemental Cash Flow Information
Cash Paid For:
Income taxes	$	462		$	106
Interest		112			44
Supplemental Noncash Investing and Financing Activities:
Deferred payments for purchases of intellectual property	$	—		$	30
Reclassification of debentures from long-term to short-term debt		—			1,971

MEDTRONIC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except per share data)


	October 27,			April 28,
	2006			2006
ASSETS

Current assets:
Cash and cash equivalents	$	1,090		$	2,994
Short-term investments		2,515			3,107
Accounts receivable, less allowances of $194 and $184, respectively		2,590			2,429
Inventories		1,318			1,177
Deferred tax assets, net		414			197
Prepaid expenses and other current assets		496			473

Total current assets		8,423			10,377

Property, plant and equipment		4,048			3,794
Accumulated depreciation		(2,100	)		(1,913	)

Net property, plant and equipment		1,948			1,881

Goodwill		4,361			4,346
Other intangible assets, net		1,608			1,592
Long-term investments		2,056			957
Long-term deferred tax assets, net		12			—
Other long-term assets		488			512

Total assets	$	18,896		$	19,665

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:
Short-term borrowings	$	623		$	2,437
Accounts payable		319			319
Accrued compensation		622			723
Accrued income taxes		696			461
Other accrued expenses		529			466

Total current liabilities		2,789			4,406

Long-term debt		5,487			5,486
Long-term deferred tax liabilities, net		—			22
Long-term accrued compensation		186			189
Other long-term liabilities		157			179

Total liabilities		8,619			10,282

Commitments and contingencies		—			—

Shareholders’ equity:
Preferred stock— par value $1.00		—			—
Common stock— par value $0.10		115			116
Retained earnings		9,960			9,112
Accumulated other non-owner changes in equity		202			155

Total shareholders’ equity		10,277			9,383

Total liabilities and shareholders’ equity	$	18,896		$	19,665

MEDTRONIC, INC.
REVENUE BY OPERATING SEGMENT — WORLD WIDE
(Unaudited)

($ millions)


	FY 06		FY 06			FY 06			FY 06			FY 06			FY 07		FY 07		FY 07		FY 07		FY 07
	QTR 1		QTR 2			QTR 3			QTR 4			Total			QTR 1		QTR 2		QTR 3		QTR 4		Total

REPORTED REVENUE :
CARDIAC RHYTHM DISEASE MANAGEMENT	$	1,268	$	1,289		$	1,263		$	1,385		$	5,206		$	1,250	$	1,363	$	—	$	—	$	2,613
Low Power Pacing		446		459			426			464			1,795			460		473		—		—		933
High Power Defibrillation		718		733			723			758			2,932			673		764		—		—		1,436
Emergency Response Systems		87		81			99			144			412			101		111		—		—		212
Other		17		16			15			19			67			16		15		—		—		32

SPINAL & NAVIGATION	$	524	$	539		$	563		$	619		$	2,244		$	599	$	625	$	—	$	—	$	1,224
Spinal Instrumentation		376		382			387			420			1,566			412		421		—		—		833
Spinal Biologics		128		134			147			163			570			163		178		—		—		341
Navigation		20		23			29			36			108			24		26		—		—		50

NEUROLOGICAL	$	235	$	252		$	247		$	283		$	1,016		$	276	$	291	$	—	$	—	$	567
Neuro Implantables		186		204			202			241			833			226		238		—		—		464
Gastroenterology & Urology		49		48			45			42			183			50		53		—		—		103

VASCULAR	$	205	$	225		$	236		$	274		$	940		$	280	$	287	$	—	$	—	$	567
Stents		65		90			96			114			366			120		132		—		—		252
Other Coronary		81		78			83			92			334			92		85		—		—		177
Endovascular/Peripheral		59		57			57			68			240			68		70		—		—		138

DIABETES	$	173	$	178		$	182		$	188		$	722		$	196	$	212	$	—	$	—	$	408

CARDIAC SURGERY	$	165	$	161		$	154		$	183		$	663		$	168	$	168	$	—	$	—	$	336
Valves		58		56			52			63			229			59		59		—		—		119
Perfusion		79		78			75			89			321			80		81		—		—		161
Cardiac Surgery Technologies		28		27			27			31			113			29		28		—		—		56

EAR, NOSE & THROAT (ENT)	$	120	$	121		$	125		$	135		$	501		$	128	$	129	$	—	$	—	$	257
ENT		65		64			65			72			266			65		65		—		—		131
Neurologic Technologies		55		57			60			63			235			63		64		—		—		126

TOTAL	$	2,690	$	2,765		$	2,770		$	3,067		$	11,292		$	2,897	$	3,075	$	—	$	—	$	5,972


ADJUSTMENTS :

CURRENCY (1)	$	26	$	(3	)	$	(72	)	$	(69	)	$	(118	)	$	6	$	33					$	39

COMPARABLE OPERATIONS (1)	$	2,664	$	2,768		$	2,842		$	3,136		$	11,410		$	2,891	$	3,042	$	—	$	—	$	5,933


(1)		Medtronic management believes that in order to properly understand Medtronic’s short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenues.

MEDTRONIC, INC.
REVENUE BY OPERATING SEGMENT — US
(Unaudited)

($ millions)


	FY 06		FY 06		FY 06		FY 06		FY 06		FY 07		FY 07		FY 07		FY 07		FY 07
	QTR 1		QTR 2		QTR 3		QTR 4		Total		QTR 1		QTR 2		QTR 3		QTR 4		Total

REPORTED REVENUE :

CARDIAC RHYTHM DISEASE MANAGEMENT	$	857	$	879	$	862	$	899	$	3,496	$	793	$	880	$	—	$	—	$	1,672
Low Power Pacing		218		235		223		227		902		228		244		—		—		471
High Power Defibrillation		571		579		565		569		2,283		495		554		—		—		1,049
Emergency Response Systems		59		54		65		94		273		60		73		—		—		133
Other		9		11		9		9		38		10		9		—		—		19

SPINAL & NAVIGATION	$	437	$	454	$	477	$	511	$	1,881	$	497	$	522	$	—	$	—	$	1,019
Spinal Instrumentation		300		308		315		328		1,252		322		333		—		—		655
Spinal Biologics		124		131		143		158		557		158		172		—		—		329
Navigation		13		15		19		25		72		17		17		—		—		35

NEUROLOGICAL	$	162	$	185	$	182	$	197	$	726	$	196	$	215	$	—	$	—	$	411
Neuro Implantables		126		148		149		169		592		157		173		—		—		331
Gastroenterology & Urology		36		37		33		28		134		39		42		—		—		80

VASCULAR	$	66	$	66	$	67	$	76	$	275	$	79	$	83	$	—	$	—	$	162
Stents		6		6		6		6		24		9		12		—		—		21
Other Coronary		26		26		27		32		111		31		30		—		—		62
Endovascular/Peripheral		34		34		34		38		140		39		41		—		—		79

DIABETES	$	130	$	134	$	136	$	134	$	534	$	140	$	154	$	—	$	—	$	294

CARDIAC SURGERY	$	92	$	90	$	84	$	100	$	366	$	91	$	91	$	—	$	—	$	183
Valves		35		33		31		38		138		35		35		—		—		70
Perfusion		41		41		38		44		163		40		40		—		—		81
Cardiac Surgery Technologies		16		16		15		18		65		16		16		—		—		32

EAR, NOSE & THROAT (ENT)	$	84	$	85	$	88	$	92	$	348	$	87	$	88	$	—	$	—	$	175
ENT		46		45		46		49		184		43		44		—		—		87
Neurologic Technologies		38		40		42		43		164		44		44		—		—		88

TOTAL	$	1,828	$	1,893	$	1,896	$	2,009	$	7,626	$	1,883	$	2,033	$	—	$	—	$	3,916


ADJUSTMENTS :

CURRENCY	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—

COMPARABLE OPERATIONS	$	1,828	$	1,893	$	1,896	$	2,009	$	7,626	$	1,883	$	2,033	$	—	$	—	$	3,916


Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenues.

MEDTRONIC, INC.
REVENUE BY OPERATING SEGMENT — INTERNATIONAL
(Unaudited)

($ millions)


	FY 06		FY 06			FY 06			FY 06			FY 06			FY 07		FY 07		FY 07		FY 07		FY 07
	QTR 1		QTR 2			QTR 3			QTR 4			Total			QTR 1		QTR 2		QTR 3		QTR 4		Total

REPORTED REVENUE :

CARDIAC RHYTHM DISEASE MANAGEMENT	$	411	$	410		$	401		$	486		$	1,710		$	457	$	483	$	—	$	—	$	941
Low Power Pacing		228		224			203			237			893			232		229		—		—		462
High Power Defibrillation		147		154			158			189			649			178		210		—		—		387
Emergency Response Systems		28		27			34			50			139			41		38		—		—		79
Other		8		5			6			10			29			6		6		—		—		13

SPINAL & NAVIGATION	$	87	$	85		$	86		$	108		$	363		$	102	$	103	$	—	$	—	$	205
Spinal Instrumentation		76		74			72			92			314			90		88		—		—		178
Spinal Biologics		4		3			4			5			13			5		6		—		—		12
Navigation		7		8			10			11			36			7		9		—		—		15

NEUROLOGICAL	$	73	$	67		$	65		$	86		$	290		$	80	$	76	$	—	$	—	$	156
Neuro Implantables		60		56			53			72			241			69		65		—		—		133
Gastroenterology & Urology		13		11			12			14			49			11		11		—		—		23

VASCULAR	$	139	$	159		$	169		$	198		$	665		$	201	$	204	$	—	$	—	$	405
Stents		59		84			90			108			342			111		120		—		—		231
Other Coronary		55		52			56			60			223			61		55		—		—		115
Endovascular/Peripheral		25		23			23			30			100			29		29		—		—		59

DIABETES	$	43	$	44		$	46		$	54		$	188		$	56	$	58	$	—	$	—	$	114

CARDIAC SURGERY	$	73	$	71		$	70		$	83		$	297		$	77	$	77	$	—	$	—	$	153
Valves		23		23			21			25			91			24		24		—		—		49
Perfusion		38		37			37			45			158			40		41		—		—		80
Cardiac Surgery Technologies		12		11			12			13			48			13		12		—		—		24

EAR, NOSE & THROAT (ENT)	$	36	$	36		$	37		$	43		$	153		$	41	$	41	$	—	$	—	$	82
ENT		19		19			19			23			82			22		21		—		—		44
Neurologic Technologies		17		17			18			20			71			19		20		—		—		38

TOTAL	$	862	$	872		$	874		$	1,058		$	3,666		$	1,014	$	1,042	$	—	$	—	$	2,056


ADJUSTMENTS :

CURRENCY (1)	$	26	$	(3	)	$	(72	)	$	(69	)	$	(118	)	$	6	$	33	$	—	$	—	$	39

COMPARABLE OPERATIONS (1)	$	836	$	875		$	946		$	1,127		$	3,784		$	1,008	$	1,009	$	—	$	—	$	2,017


(1)		Medtronic management believes that in order to properly understand Medtronic’s short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenues.